Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 116 Parkinson's papers of 5,804 | 0.37 |
| pathways Reactome | 4 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 2956
Sealed predictions
- ATG5 in dopamine neurons, braak+0.16 (p 0.685) → +0.06 (p 0.886)receipt 2964
Swarm cases
receipt 2964: ATG5 in dopamine neurons, braak
- power
- full sample +0.10 (p 0.683, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.20 (p 0.424, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.16 (p 0.538, n 18). could be the mix.
- skeptic
- leave-one-out range -0.00 to +0.24, sign flips 1; without severely affected donors +0.10 (p 0.683, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATG5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts